Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed metastatic adenocarcinoma of the pancreas

- Progressed after first-line or adjuvant gemcitabine-based chemotherapy

- Measurable disease as assessed by RECIST criteria

- No known brain metastasis or symptomatic carcinomatous leptomeningitis

PATIENT CHARACTERISTICS:

- WHO performance status 0-1

- Life expectancy ≥ 3 months

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥ 9 g/dL

- Creatinine ≤ 1.5 times upper limit of normal (ULN)

- Total bilirubin ≤ 2.5 times ULN

- ALT/AST ≤ 5 times ULN

- LVEF ≥ 55%

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No significant comorbidities, including any of the following:

- Cardiovascular disease

- Documented history of congestive heart failure

- Uncontrolled, high-risk arrhythmia

- Angina pectoris requiring treatment

- Clinically significant valvular disease

- Evidence of transmural myocardial infarction by ECG

- Uncontrolled hypertension

- Active bleeding

- Clinically significant active infection

- Severe dyspnea at rest

- Oxygen-dependency

- No other malignancy except basal cell carcinoma of the skin

- No severe hypersensitivity to cetuximab or trastuzumab

- No medical or psychological condition that would preclude study completion or giving
informed consent

- No legal incapacity or limited legal capacity

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior cetuximab or trastuzumab

- No other concurrent experimental drugs or anticancer therapy